Biliverdin reductase B as a new target in breast cancer.

Breast Cancer Res · 2025 · PMC12532840 · PMID 41102733

Europe PMC DOI

hedged sentence

0.0000

closest p · 0.0× alpha

0.0000

boldest claim

The sentences

highly significantp = 1.30 × 10 −22actually significant

Correlation analysis using TCGA database (N = 1,082) across all breast cancer subtypes revealed a highly significant association between ErbB2 and BLVRB expression (ρ = 0.291, p = 1.30 × 10 −22 , Fig. 6 L).

also in 82,756 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.